RALEIGH, N.C., Dec. 27 /PRNewswire/ -- Voyager Pharmaceutical Corporation, the specialty pharmaceutical company focused on diseases of aging and development, announced Tuesday the promotion of Dr. Christopher Gregory to the position of Vice President of Research. Gregory has been responsible for establishing Voyager’s Invention Center (VIC) in Research Triangle Park, N.C.; his team of scientists is exploring numerous opportunities to broaden product applications based on the Company’s scientific platform.
“Chris has demonstrated sharp scientific and business acumen since he joined Voyager in 2004, so I am pleased to announce his promotion,” said Patrick Smith, the company’s president and CEO. “His leadership thus far has resulted in a number of new patent filings in areas such as prostate and brain cancer research. The work he oversees at the VIC will help broaden and strengthen our pipeline opportunities in the future.”
Gregory came to Voyager from the University of North Carolina at Chapel Hill, where he served as assistant professor in Department of Pathology and Laboratory Medicine and research assistant professor in the laboratories of Reproductive Biology and the Department of Pediatrics. During Dr. Gregory’s ten years at UNC-Chapel Hill, he published numerous papers in peer-reviewed journals and received several grants from the National Institutes of Health and the Department of Defense for his work in prostate cancer.
Gregory holds a doctoral degree in anatomy from Ohio State University and an undergraduate degree from Concord College.
About Voyager Pharmaceutical Corporation
Voyager Pharmaceutical Corporation is a biopharmaceutical company focused on developing drugs for diseases associated with aging and development. Voyager’s scientific approach is based on the observation that many diseases of aging may be caused by changes in human reproductive hormone levels that are characteristic of the aging process. Voyager’s most advanced product candidate is Memryte, a proprietary, small, biodegradable implant that is comprised of leuprolide acetate and a polymer, that is currently in phase III clinical studies (the ALADDIN study) for the treatment of mild to moderate Alzheimer’s disease. Voyager was founded in 2001 and is headquartered in Raleigh, N.C.
Contact Information:
Patrick S. Smith, President and CEO
Office: 919.846.4880
Voyager Pharmaceutical Corporation
CONTACT: Patrick S. Smith, President and CEO of Voyager PharmaceuticalCorporation, +1-919-846-4880
